PNP18 FORMULARY DECISION SUPPORT FOR INTERFERON-BETA-1A USING ANALYSIS OF CARE-SEEKING BEHAVIOR FOR MULTIPLE SCLEROSIS  by Meyer, C et al.
513Abstracts
50% reduction in seizures. The mean utility value of
patients who prematurely discontinued treatment (n = 50)
was 0.846 (VAS = 64.89). CONCLUSIONS: More fre-
quent epilepsy seizures were associated with lower utility
values in this prospective study of patients with active
epilepsy. In addition, patients who became seizure-free on
treatment reported higher utility gains than those who
failed to respond. Better seizure control may result in
utility gains in epilepsy patients.
NEUROLOGICAL DIESEASES/DISORDERS &
PAIN—Healthcare Policy
PNP16
MEDICATION USE IN PATIENTS WITH LOW
BACK PAIN: DATA FROM MANAGED CARE
Harley C1, Wagner S2, Nelson M1
1Ingenix, Eden Prairie, MN, USA; 2Pharmacia Corporation,
Peapack, NJ, USA
OBJECTIVES: Low back pain is a serious problem that
results in lost time from work and reduced quality of life.
The annual cost of low back pain in the United States is
estimated to be billions of dollars. The primary objective
of this study was to characterize the most commonly used
drug therapies for treatment of low back pain in a
managed care organization (MCO). METHODS: We per-
formed a retrospective analysis on enrollment, medical,
and pharmacy claims data from 19 discounted, fee-
for-service, independent practice association model plans
afﬁliated with a large MCO. Commercial members with
a claim for low back pain identiﬁed by appropriate ICD-
9 codes during a speciﬁed 6-month period were included
for analysis. Results were stratiﬁed based on the follow-
ing treatment patterns: new treatment, ongoing treat-
ment, and no treatment. RESULTS: About half of the
96,024 diagnosed patients did not ﬁll a prescription, and
the new and ongoing treatment groups were about evenly
split. Mean age was 42 years, with 46.7% male. About
half of subjects received >1 drug. In both the new and
ongoing groups hydrocodone/acetaminophen was the
most common pain medication for both groups, 
prescribed in 27.7% and 41.2% of cases, respectively.
Naproxen was the second most prescribed drug for newly
treated patients (25.8%) and cyclopbenzaprine (21%) the
second most prescribed drug in the ongoing group. Oxy-
codone/acetaminophen was used in 7.6% of the newly
treated patients and in 13% of the ongoing group. Oxy-
codone was used in 8.1% of the ongoing group, but was
not among the top 20 drugs prescribed in the newly
treated group. CONCLUSIONS: We observed titration in
treatment for pain in the ongoing users who switched to
more potent, long-acting medications to control their low
back pain. The increased utilization of narcotic analgesics
could have signiﬁcant quality of care, productivity, 
disability, and cost implications.
PNP17
COMPLIANCE OF TWO TREATMENTS OF
ALZHEIMER’S DISEASE
Barbeau M, Baladi JF
Novartis Pharma Canada Inc, Dorval, QC, Canada
OBJECTIVE: Compliance with Alzheimer’s Disease (AD)
medication is an important determinant of their effec-
tiveness. This study tests whether differences in com-
pliance were observed with two AD medications that
have different administration schedules (od versus bid).
METHOD: Data for ﬁrst-time users of donepezil and
rivastigmine between October 1, 2000 and March 31,
2002 were extracted from the Quebec Health Insurance
Board database. Two cohorts were identiﬁed: rivastig-
mine and donepezil. Information on sex, age and com-
pliance was gathered at 3, 6, 9 and 12 month following
their ﬁrst prescription. Compliance was measured by
using the total number of days covered by patients’ 
prescriptions within the 3, 6, 9 or 12 month period. 
If patients consumed at least 80% of their medication
they were assumed to be compliant. Statistical difference
at 95% between the proportions in each group was
assessed. RESULTS: A total of 6267 patients (69% of
women) with a mean age of 78.6 in the donepezil cohort
and 773 (48% of women) with a mean age of 77.3 in the
rivastigmine group were identiﬁed. At month 3, no 
statistical difference (CI: -0.82–0.88) in compliance
between donepezil (77.6%) and rivastigmine (74.6%)
was detected. The same conclusion was reached for the
analysis at month 6, 9 and 12. Of note, a large decrease
in the compliance in both groups was observed from
month 3 to month 12. However, the trend is very similar
in both groups. CONCLUSION: No statistically signiﬁ-
cant difference in compliance was observed between
patients on rivastigmine and donepezil. Furthermore, no
difference in the compliance trend (from month 3 to 12)
in both groups was observed. Finally, compliance with
AD medication did not seem to differ depending of the
administration schedules (od versus bid).
PNP18
FORMULARY DECISION SUPPORT FOR
INTERFERON-BETA-1A USING ANALYSIS 
OF CARE-SEEKING BEHAVIOR FOR 
MULTIPLE SCLEROSIS
Meyer C1, Phipps R2, Cooper D1, Neff S1,Wright A1
1AdvancePCS, Hunt Valley, MD, USA; 2Serono, Inc, Rockland,
MA, USA
OBJECTIVE: To estimate the incremental pharmacy
PMPM change according to various formulary designs 
for interferon-beta-1a using administrative claims data
METHODS: Cross-sectional sex- and age-speciﬁc disease
prevalence and treatment rates for multiple sclerosis (MS)
patients were measured using integrated medical and
pharmacy claims data from a 508,066-member employer
514 Abstracts
group in the southern U.S. Migration to interferon-
beta-1a from competitors was based on market-share
data for new and existing MS patients. Duration of
therapy was estimated by analyzing claims for current MS
therapies. Daily therapy cost was provided by the manu-
facturer, adjusted for migration from other therapies, and
multiplied by estimated volume to predict incremental
and total per-member, per-month (PMPM) impact.
Market-share estimates were used to develop a PMPM
forecast for the next two years. PMPM estimates were
calculated for preferred and non-preferred formulary tier
designs with and without prior authorization (PA). One-
way sensitivity analysis was performed to assess inﬂuence
of product pricing, duration of therapy, and other market
factors. RESULTS: Annual incremental PMPM change
was $0.047 for the third co-payment tier with PA sce-
nario. The incremental change was greatest for those 
aged 55 to 65 years ($0.056 PMPM) and did not vary
greatly by beneﬁt design. Duration of therapy has the
greatest impact on the PMPM estimate across beneﬁt
designs. CONCLUSIONS: Interferon-beta-1a will not
cause a signiﬁcant change in managed care pharmacy
budgets under a variety of formulary conditions, accord-
ing to this cross-sectional analysis of current care-seeking
behavior by MS patients. Economic impact may differ 
if interferon-beta-1-a expands MS patients’ treatment-
seeking behavior.
MENTAL HEALTH—Economic Outcomes
PMH1
THE HEALTH CARE COSTS OF
SCHIZOPHRENIA IN AUSTRALIA: 18-MONTH
FOLLOW-UP RESULTS
Christova L1, Davey P1, Jackson D1, Montgomery W2,
deCastella A3, Fitzgerald P3, Brewer K3, Filia K3, Collins J3,
Kulkarni J3
1Medical Technology Assessment Group, Chatswood West,
NSW, Australia; 2Eli Lilly Australia Pty Ltd, West Ryde, NSW,
Australia; 3Dandenong Hospital Dept of Psychiatry,
Dandenong,VIC, Australia
OBJECTIVE: Schizophrenia is a chronic condition asso-
ciated with a signiﬁcant burden of disease and high health
care costs. The Schizophrenia Care and Assessment
Program (SCAP) is a naturalistic, observational study that
aims to collect information on a range of treatment out-
comes (clinical, functional and social) as well as detailed
information on health care service utilisation and associ-
ated costs. METHODS: The Australian arm of this study
involves 350 participants recruited from a large regional
mental health service in outer Melbourne. Participants are
assessed every six months. Health care resource data are
collected via a combination of electronic systems, includ-
ing a national medical and prescription claims database,
a state-based patient registry and a hospital pharmacy
information management system. RESULTS: The ﬁrst 18-
month longitudinal analysis of the complete SCAP cohort
reveals that the average total cost of health care services
and medications per patient during the 18 months was
AUD21,287 (€12,559). The most expensive component
of the total costs was inhospital treatment (71%), 
followed by outpatient services (17%) and medications
(12%). The average cost of medications dispensed to 
the subjects during the 18-month period was AUD2570
(€1516). Eighty percent of the subjects had medication
costs of less than AUD5000. In contrast, 2.3% of sub-
jects had costs greater than AUD10,000 (€5900) and
accounted for 10% of the total medication costs. CON-
CLUSIONS: While medications remain an important part
of the treatment strategy for people with schizophrenia,
they are only a small proportion of the overall cost 
of care. The most expensive component is inhospital
treatment.
PMH2
ANTIPSYCHOTIC USE PATTERNS AND
HEALTHCARE COSTS FOR INDIVIDUALS 
WITH SCHIZOPHRENIA TREATED WITH
HALOPERIDOL, OLANZAPINE OR 
RISPERIDONE IN A MEDICAID 
POPULATION
Ramsey JL1, Hutchins D2, Zhu B1, Zhao Z1, Gibson PJ1,
Lothgren M3
1Eli Lilly and Company, Indianapolis, IN, USA; 2Advance PCS,
Scottsdale, AZ, USA; 3Eli Lilly and Company, Windelsham,
Surrey, United Kingdom
OBJECTIVE: To evaluate medication use patterns and
healthcare costs for individuals with schizophrenia
treated with haloperidol, olanzapine or risperidone in a
Medicaid program. METHODS: Medicaid recipients
who were diagnosed with schizophrenia (ICD-9 295.XX)
and began treatment with haloperidol (n = 302), olanza-
pine (n = 895), or risperidone (n = 479) between January
1997 and June 1997 were followed for 1 year. Me-
dical service and pharmacy claims one-year prior and
post-initiation were extracted and analyzed. Length of 
treatment, total and component healthcare costs were
compared using regression models controlling for demo-
graphic and clinical characteristics and previous service
and medication use. RESULTS: Compared to haloperidol
and risperidone users, patients using olanzapine stayed on
therapy signiﬁcantly longer (+69 days vs. haloperidol, p
< .0001; +29 days vs. risperidone, p < .0001). Olanzap-
ine patients had higher antipsychotic medication costs
(+$1269 vs. haloperidol, p < .0001; +$562 vs. risperi-
done, p < .0001) but lower psychiatric inpatient costs 
(-$1713 vs. haloperidol, p = .02; -$305 vs. risperidone,
p = 0.62). There were no signiﬁcant differences in total
healthcare costs (-$304 vs. haloperidol, p = .74 and -$49
vs. risperidone, p = .95). CONCLUSION: Longer treat-
ment duration, reductions in hospitalization costs and
similar total costs associated with olanzapine treatment
may be indicative of better patient outcomes.
